Loading...

Gritstone Oncology

Nasdaq:GRTS
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GRTS
Nasdaq
$399M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. The last earnings update was 7 days ago. More info.


Add to Portfolio Compare Print
  • Gritstone Oncology has significant price volatility in the past 3 months.
GRTS Share Price and Events
7 Day Returns
1.5%
NasdaqGS:GRTS
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
-
NasdaqGS:GRTS
-5.5%
US Biotechs
3%
US Market
GRTS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Gritstone Oncology (GRTS) 1.5% -18.6% -4% - - -
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • No trading data on GRTS.
  • No trading data on GRTS.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Gritstone Oncology undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Gritstone Oncology. This is due to cash flow or dividend data being unavailable. The share price is $11.18.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Gritstone Oncology's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Gritstone Oncology's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:GRTS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-4.45
NasdaqGS:GRTS Share Price ** NasdaqGS (2019-05-17) in USD $11.18
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Gritstone Oncology.

NasdaqGS:GRTS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:GRTS Share Price ÷ EPS (both in USD)

= 11.18 ÷ -4.45

-2.51x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gritstone Oncology is loss making, we can't compare its value to the US Biotechs industry average.
  • Gritstone Oncology is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Gritstone Oncology's expected growth come at a high price?
Raw Data
NasdaqGS:GRTS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.51x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-27.4%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Gritstone Oncology, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Gritstone Oncology's assets?
Raw Data
NasdaqGS:GRTS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $4.56
NasdaqGS:GRTS Share Price * NasdaqGS (2019-05-17) in USD $11.18
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqGS:GRTS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:GRTS Share Price ÷ Book Value per Share (both in USD)

= 11.18 ÷ 4.56

2.45x

* Primary Listing of Gritstone Oncology.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Gritstone Oncology is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Gritstone Oncology's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Gritstone Oncology has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Gritstone Oncology expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-27.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Gritstone Oncology expected to grow at an attractive rate?
  • Unable to compare Gritstone Oncology's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Gritstone Oncology's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Gritstone Oncology's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:GRTS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:GRTS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -27.4%
NasdaqGS:GRTS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 33.4%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:GRTS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:GRTS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 15 -238 -279 4
2022-12-31 7 -194 -168 4
2021-12-31 5 -124 -141 6
2020-12-31 4 -110 -104 6
2019-12-31 5 -88 -87 4
NasdaqGS:GRTS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 3 -42 -69
2018-12-31 1 -38 -65
2018-09-30 0 -40 -65
2018-06-30 -49 -56
2018-03-31 -44 -47
2017-12-31 -35 -41
2016-12-31 -15 -19

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Gritstone Oncology is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Gritstone Oncology's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:GRTS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Gritstone Oncology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:GRTS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -4.04 -2.31 -6.05 3.00
2022-12-31 -4.04 -2.81 -5.80 3.00
2021-12-31 -3.40 -2.39 -5.05 4.00
2020-12-31 -2.93 -2.45 -3.68 4.00
2019-12-31 -2.62 -2.49 -2.87 4.00
NasdaqGS:GRTS Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -4.45
2018-12-31 -7.26
2018-09-30 -28.35
2018-06-30 -25.44
2018-03-31 -22.86
2017-12-31 -20.70
2016-12-31 -11.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Gritstone Oncology will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Gritstone Oncology's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Gritstone Oncology has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Gritstone Oncology performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Gritstone Oncology's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Gritstone Oncology does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Gritstone Oncology's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Gritstone Oncology's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Gritstone Oncology's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Gritstone Oncology Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:GRTS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2.53 -69.41 14.15
2018-12-31 1.19 -64.78 11.81
2018-09-30 0.10 -64.81 9.77
2018-06-30 -55.67 8.08
2018-03-31 -47.47 6.69
2017-12-31 -41.38 6.07
2016-12-31 -18.75 5.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Gritstone Oncology has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Gritstone Oncology has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Gritstone Oncology improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Gritstone Oncology's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Gritstone Oncology has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Gritstone Oncology's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Gritstone Oncology's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Gritstone Oncology is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Gritstone Oncology's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Gritstone Oncology's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 6.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Gritstone Oncology Company Filings, last reported 1 month ago.

NasdaqGS:GRTS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 132.22 19.68 132.16
2018-12-31 149.12 10.49 153.11
2018-09-30 72.69 10.50 77.42
2018-06-30 78.67 10.51 64.49
2018-03-31 97.28 10.52 85.95
2017-12-31 97.28 10.52 85.95
2016-12-31 41.69 0.00 37.51
  • Gritstone Oncology's level of debt (14.9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Gritstone Oncology's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Gritstone Oncology has sufficient cash runway for 2.7 years based on current free cash flow.
  • Gritstone Oncology has sufficient cash runway for 2.3 years if free cash flow continues to grow at historical rates of 22.2% each year.
X
Financial health checks
We assess Gritstone Oncology's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Gritstone Oncology has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Gritstone Oncology's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Gritstone Oncology dividends. Estimated to be 0% next year.
If you bought $2,000 of Gritstone Oncology shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Gritstone Oncology's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Gritstone Oncology's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:GRTS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:GRTS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Gritstone Oncology has not reported any payouts.
  • Unable to verify if Gritstone Oncology's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Gritstone Oncology's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Gritstone Oncology has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Gritstone Oncology's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Gritstone Oncology's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Gritstone Oncology afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Gritstone Oncology has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Gritstone Oncology's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Andrew Allen
COMPENSATION $1,652,416
AGE 51
TENURE AS CEO 3.7 years
CEO Bio

Dr. Andrew R. Allen, BM, BCh, MA, MRCP, M.D., Ph.D., co-founded Gritstone Oncology Inc. and has been its Chief Executive Officer and President since September 2015. Dr. Allen advises Epic Sciences (La Jolla, CA). He Co-founded Clovis Oncology, Inc. in April 20, 2009 and served as its Chief Medical officer and Executive Vice President of Clinical & Pre-Clinical Development from April 20, 2009 to August 2015. He served as the Chief Medical Officer of Pharmion LLC since May 18, 2006 and served as its Executive Vice President since August 2006. He served as a Vice President of BioPharma Development and Head of the Oncology Therapeutic Unit for Chiron Corporation from 2004 to 2006. He served as Global Project Head in Abbott Laboratories' oncology franchise and he progressed through positions of increasing responsibility at McKinsey & Company, in the development and execution of business strategies for top-tier biotechnology and pharmaceutical companies, with a focus on oncology. He serves as the Chairman of Revitope Oncology, Inc. He has been a Director of Sierra Oncology, Inc. since October 23, 2017. He serves as a Director of TCR2 Inc. since December 19, 2018. He has been an Independent Director of Epizyme, Inc. since June 9, 2014. He serves as a Member of Scientific Advisory Board of Predictive Biomarker Sciences, Inc. He has been a Director of Gritstone Oncology Inc. since September 2015. He served as a Director at Nodality Inc. He was Director at Cell Design Labs, Inc. until 2017. He was practicing as a Nephrologist (focus on transplantation and immune-mediated glomerulonephritis) at Hammersmith Hospital in London. Dr. Allen received a medical degree from Oxford University. He qualified in Medicine at Oxford University and holds a Ph.D. in Immunology from the Imperial College of Science, Technology and Medicine in London. Dr. Allen obtained Post-Graduate Internal Medicine Qualification as a Member of Royal College of Physicians (MRCP).

CEO Compensation
  • Andrew's compensation has increased whilst company is loss making.
  • Andrew's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Gritstone Oncology management team in years:

3
Average Tenure
46
Average Age
  • The tenure for the Gritstone Oncology management team is about average.
Management Team

Andrew Allen

TITLE
Co-Founder
COMPENSATION
$2M
AGE
51
TENURE
3.7 yrs

Jean-Marc Bellemin

TITLE
Executive VP of Finance & CFO
COMPENSATION
$1M
AGE
46
TENURE
1.3 yrs

Roman Yelensky

TITLE
Executive VP & CTO
COMPENSATION
$943K
AGE
39
TENURE
3.6 yrs

Karin Jooss

TITLE
Executive VP of Research & Chief Scientific Officer
COMPENSATION
$504K
AGE
53
TENURE
3.1 yrs

Mike Forcht

TITLE
Senior Vice President of Human Resources
TENURE
0.2 yrs

Matthew Hawryluk

TITLE
Executive VP & Chief Business Officer
AGE
40
TENURE
3.5 yrs

Erin Jones

TITLE
Executive VP and Global Head of Regulatory Affairs & Quality Assurance
AGE
46
TENURE
3 yrs

Raphaël Rousseau

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$787K
AGE
49
TENURE
2.1 yrs
Board of Directors Tenure

Average tenure and age of the Gritstone Oncology board of directors in years:

3.2
Average Tenure
52.5
Average Age
  • The tenure for the Gritstone Oncology board of directors is about average.
Board of Directors

Andrew Allen

TITLE
Co-Founder
COMPENSATION
$2M
AGE
51
TENURE
3.7 yrs

Tom Woiwode

TITLE
Director
COMPENSATION
$12K
AGE
46
TENURE
3.7 yrs

Judith Li

TITLE
Director
COMPENSATION
$11K
AGE
34
TENURE
1.7 yrs

Steve Krognes

TITLE
Director
COMPENSATION
$126K
AGE
50
TENURE
0.8 yrs

Naiyer Rizvi

TITLE
Co-Founder & Member of Scientific Advisory Board
AGE
54
TENURE
2.9 yrs

Rich Heyman

TITLE
Director
COMPENSATION
$47K
AGE
61
TENURE
3.5 yrs

Peter Svennilson

TITLE
Director
COMPENSATION
$11K
AGE
56
TENURE
3.7 yrs

Nick Simon

TITLE
Director
COMPENSATION
$11K
AGE
64
TENURE
3.7 yrs

James Gulley

TITLE
Member of Scientific Advisory Board
TENURE
1.9 yrs

Timothy Chan

TITLE
Co-Founder & Member of Scientific Advisory Board
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
02. Oct 18 Buy Clarus Ventures, LLC Company 28. Sep 18 28. Sep 18 333,333 $15.00 $4,999,995
X
Management checks
We assess Gritstone Oncology's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Gritstone Oncology has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Could The Gritstone Oncology, Inc. (NASDAQ:GRTS) Ownership Structure Tell Us Something Useful?

Insider Ownership Of Gritstone Oncology The definition of company insiders can be subjective, and does vary between jurisdictions. … But other times, private equity is selling out, having taking the company public. … Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.

Simply Wall St -

Company Info

Description

Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.

Details
Name: Gritstone Oncology, Inc.
GRTS
Exchange: NasdaqGS
Founded: 2015
$399,337,000
35,718,873
Website: http://gritstoneoncology.com
Address: Gritstone Oncology, Inc.
5858 Horton Street,
Suite 210,
Emeryville,
California, 94608,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS GRTS Common Stock Nasdaq Global Select US USD 28. Sep 2018
DB 2JQ Common Stock Deutsche Boerse AG DE EUR 28. Sep 2018
BST 2JQ Common Stock Boerse-Stuttgart DE EUR 28. Sep 2018
Number of employees
Current staff
Staff numbers
127
Gritstone Oncology employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 03:31
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/13
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.